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To assess the prevalence, timing and functional impact of psychiatric, 
cognitive and motor abnormalities in Huntington’s disease (HD) gene carriers, 
we analysed retrospective clinical data from individuals with manifest HD. 
 
Methods 
Clinical features of HD patients were analysed for 6316 individuals in the 
European REGISTRY study from 161 sites across 17 countries.  Data came 
from clinical history and the patient-completed Clinical Characteristics 
Questionnaire that assessed eight symptoms: motor, cognitive, apathy, 
depression, perseverative/obsessive behavior, irritability, violent/aggressive 
behavior, and psychosis. Multiple logistic regression was used to analyse 
relationships between symptoms and functional outcomes. 
 
Results 
The initial manifestation of HD is increasingly likely to be motor, and less likely 
to be psychiatric, as age at presentation increases, and is independent of 
pathogenic CAG repeat length. The Clinical Characteristics Questionnaire 
captures data on non-motor symptom prevalence that correlate specifically 
with validated clinical measures. Psychiatric and cognitive symptoms are 
common in HD gene carriers, with earlier onsets associated with longer CAG 
repeats. 42.4% of HD patients reported at least one psychiatric or cognitive 
symptom before motor symptoms, with depression most common. Each non-
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Psychiatric and cognitive symptoms are common and functionally debilitating 
in HD gene carriers. They require recognition and targeting with clinical 
outcome measures and treatments. However, as it is impossible to distinguish 
confidently between non-motor symptoms arising from HD and primary 
psychiatric disorders, particularly in younger pre-manifest patients, non-motor 
symptoms should not be used to make a clinical diagnosis of HD. 
 




Huntington’s disease (HD) is a central neurodegenerative disorder caused by 
an expanded CAG repeat (>35 CAGs) in the Huntingtin gene1. Longer 
repeats are associated with earlier disease onset2,3. Neuronal loss in the brain 
causes progressive motor abnormalities, cognitive decline and ultimately 
death. The movement disorder usually includes chorea, but may also involve 
dystonia, ataxia, oculomotor problems and parkinsonism, some of which are 
initially only identifiable through targeted HD examination. Debilitating 
behavioral and psychiatric symptoms are common in HD gene carriers, and 
require treatment, although they cannot be used in clinical practice to define 
HD onset because it is impossible to distinguish psychiatric manifestations of 
HD from coincident diagnoses4,5. Prospective studies of HD gene carriers 
many years from predicted clinical onset have shown only subtle motor, 
cognitive and psychiatric deficits when compared with age and sex-matched 
controls6–8. This implies there is a window for therapeutic intervention to 
preserve normal brain functions. Understanding in detail the timing and impact 
of different symptoms in HD gene carriers will help improve targeted 
therapies. 
The HD Clinical Characteristics Questionnaire (HD-CCQ)9 gathers 
retrospective data from individuals with HD about the prevalence and timing of 
eight motor, cognitive and psychiatric symptoms10. Here we validate HD-CCQ 
data for non-motor symptoms by showing strong and specific associations 
with established scores of depression, irritability and cognition. We use HD-
CCQ data to show the high prevalence of psychiatric and cognitive symptoms 
in HD gene carriers, often in advance of motor symptoms, and their negative 
impact on the lives of patients. 
 





Standard protocol approvals, registrations, and patient consents 
Participants were in the multicentre, multinational, observational REGISTRY 
study of European HD (http://www.ehdn.org/wp-
content/uploads/2018/06/registry-protocol-3.0.pdf; NCT01590589). Data were 
accessed as part of European Huntington’s Disease Network (EHDN) data 
mining project 0791. Ethical approval for REGISTRY was obtained in each 
participating country. All participants gave written informed consent. 
 
Participant data 
HD participant data, collected June 2004 - February 2016 across 161 sites in 
17 European countries, was obtained for 6316 individuals (accessed October 
2016) who had clinical HD onset, determined by the rating clinician in 
REGISTRY, and a confirmed pathogenic CAG length of 36-93 CAGs. Of 
these CAG sizes, 5027 were centrally determined by BioRep Inc. (Milan, Italy; 
REGISTRY protocols) and 1289 were derived by local diagnostic laboratories. 
Two estimates of the age at onset of symptoms and/or signs in HD were used 
in this study. First, the clinician-estimated age at first HD manifestation based 
upon all available clinical evidence at the first REGISTRY visit (coded as 
‘sxrater’). Having a ‘sxrater’ age at onset was required for inclusion in this 
study. Onset type was classified as motor, cognitive, psychiatric, oculomotor, 
other or mixed. As the clinician’s estimate was given as a date, age estimates 
were calculated using the participant’s anonymised birthday; where only a 
year was given, July 15th was used for estimation (15/07/xxxx). Second, the 
ages at onset of different symptoms in HD patients were estimated by the HD 
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Clinical Characteristics Questionnaire (HD-CCQ) which was completed by a 
healthcare professional, usually a HD-specialist nurse or similarly-qualified 
person, using responses from the individual with HD and their care partners 
(present in clinic in 93.1% of cases), and patient medical notes. The HD-CCQ 
comprises questions about eight symptoms commonly observed in HD, 
asking whether the participant has ever had the symptom (yes or no), and, if 
yes, the age at which the symptom was first experienced (Appendix 3, 
https://doi.org/10.5061/dryad.pk0p2ngkz). Information was available, at least 
in part, for 5609 individuals. The symptoms recorded (number of individuals 
with data) were: motor (chorea or other, consistent with HD; 5603), cognitive 
impairment sufficient to impact on work or daily living (5591), apathy (5584), 
depression (5595), perseverative/obsessive behaviour (5588), irritability 
(5586), violent or aggressive behaviour (5586) and psychosis (5589). For 
subsequent analyses, missing data were handled using pairwise deletion to 
maximise the number of individuals. Typically, the rater estimate of clinical 
onset and initial HD-CCQ would be recorded at the first REGISTRY visit, 
sometimes by one clinician, and sometimes by a clinician and another 
qualified staff member such as HD-specialist nurse, depending on local clinic 
set-up. Subsequent visits updated the HD-CCQ: we used data from the most 
recent clinic visit. We had data on Shoulson-Fahn disease stage at last clinic 
visit for 4554 individuals (72.1% of our study population): stage 1 (Total 
Functional Capacity (TFC) 11-13; N=890; 19.5%), stage 2 (TFC 7-10; 
N=1278; 28.1%), stage 3 (TFC 4-6; N=969; 21.3%), stage 4 (TFC 1-3; 
N=1133; 24.9%), stage 5 (TFC 0; N=284; 6.2%). 
 
The Hospital Anxiety/Depression Scale (HADS) and Snaith Irritability Scale 
(SIS) were completed by the participant at each clinic visit and provide 
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measures of anxiety, depression and irritability at that specific time. We used 
lifetime highest total depression and total irritability scores from both the 
HADS and the SIS in analyses. Similarly, the symbol-digit modalities test 
(SDMT) and Stroop tests of cognitive ability were administered as part of the 
Unified Huntington’s Disease Rating Scale (UHDRS)11 at each visit. The 
UHDRS consists of validated questionnaires, tools and examinations related 
to motor, cognitive, behavioural and functional impairments seen in HD. For 
the SDMT and Stroop, we used the total correct scores from the most recent 
clinic visit. Disease duration was estimated by taking the most recent visit and 
subtracting the clinician’s estimate of disease onset. The product of Problem 
Behaviours Assessment (PBA-s) severity and frequency scores from the most 
recent clinic was used for modelling purposes. 
 
Statistical analyses of clinical data 
Total depression scores from HADS, total irritability scores from SIS, the 
number of correct answers in the SDMT, the number of correct answers in 
Stroop tests or composite PBA-s scores were regressed on HD clinical 
characteristics data, age, CAG length, sex and disease duration (table 1). To 
calculate coefficients of determination (R2 values, table 2), HD-CCQ age at 
onset data were natural log transformed. Only individuals with a known sex 
and a symptom onset ≥3 years were considered, and a residual vs leverage 
plot identified one influential data point passing Cook’s distance that was 
removed from all R2 calculations. P values were calculated comparing male 
and female R2 values using Fisher’s transformation12. A chi-square test was 
used to test for differences in symptom frequency, derived from the yes/no 
component of the HD-CCQ, between males and females.  
 




Associations between binary responses in the HD-CCQ (1; experienced the 
symptom and 0; symptom not experienced) and clinical covariates were 
tested using logistic regression. The covariates used were sex, CAG length, 
alcohol consumption (units per week), tobacco use (cigarettes per day), 
education (years of education), TFC score and total motor score (TMS). An 
additional analysis regressed the type of HD onset defined by the clinician, 
coded as a binary variable, on the clinician’s onset or CAG length (table e-2, 
https://doi.org/10.5061/dryad.pk0p2ngkz). This analysis was restricted to HD 
participants with CAGs 36-59, to be consistent with figure 1 subgroups, and 
also to adult-onset HD individuals (≥20 years). We also tested whether 
symptom presence was associated with the length of the wild-type (6-35 
CAGs) and expanded CAGs (36-93 CAGs) alleles in individuals of known sex, 
and for whom both CAG lengths were known (table e-3, 
https://doi.org/10.5061/dryad.pk0p2ngkz). 19 individuals with a coincident 
formal diagnosis of schizophrenia, schizotypal disorder or schizoaffective 
disorder (ICD-10 F20, F21 or F25) were excluded from all models, although it 
was not possible to formally exclude these symptoms being part of the HD 




Further information and data requests should be directed to Thomas H. 
Massey (MasseyT1@cardiff.ac.uk). Anonymised summary data is available to 
qualified investigators. Furthermore, anonymised patient data is available 
from the European Huntington’s Disease Network (EHDN) upon request given 
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institutional assurance patient confidentiality will be upheld, and no attempt 
will be made to discover the identity of patients. 
 
Results 
The initial manifestation of HD varies with age and CAG length 
The age at onset of the first unequivocal motor features of HD (‘motor onset’) 
has been used as a specific milestone in the natural history of HD in 
individuals, although it is only a crude measure of a progressive 
neuropathological process. It has proven particularly useful in recent genetic 
modifier studies of HD13,14. The first psychiatric and cognitive manifestations 
of HD are more difficult to define with certainty, being less specific for HD and 
clinically indistinguishable from common coincident psychiatric diagnoses 
(e.g. depression), particularly in younger patients many years from predicted 
motor onset. The timing of the first unequivocal feature of HD is typically 
retrospectively recorded by a rating physician in observational studies such as 
REGISTRY, based on clinical information and symptom history from patients 
and care partners9,15,16. The rater also records the initial major presenting 
feature out of a choice of six: motor, cognitive, psychiatric, oculomotor, other 
or mixed. We analysed the initial manifestation of HD for 6316 participants in 
REGISTRY9, including 3083 males (48.8%) and 3233 females (51.2%). All 
participants had a confirmed genetic diagnosis of HD with a pathogenic CAG 
repeat length of 36-93 (figure e-1, https://doi.org/10.5061/dryad.pk0p2ngkz). 
The first manifestation of HD, determined by the rating physician, varied with 
patient age (figure 1A and table e-1, 
https://doi.org/10.5061/dryad.pk0p2ngkz). Individuals with onset before the 
age of 20, defined as juvenile HD, were equally likely to present with motor 
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(24.5%), cognitive (21.8%) or psychiatric features (28.2%). In contrast, the 
initial manifestation of HD was more likely to be motor than psychiatric in 
adult-onset HD. As age at first manifestation increased (figure 1A and table e-
2A, https://doi.org/10.5061/dryad.pk0p2ngkz) motor presentations became 
more likely (odds ratio (OR) = 1.06 per ten year increase in onset age, 95% 
confidence interval (CI) 1.04-1.07; P = 7.4 x 10-22) but psychiatric 
presentations became less likely (OR = 0.96 per ten year increase in onset 
age, 95% CI 0.95-0.97; P = 9.4 x 10-16). For people presenting over the age of 
60, over two-thirds (68.6%) had initial motor abnormalities with far fewer 
having psychiatric (11.5%) or cognitive (6.7%) presentations. Next, we tested 
whether there was any relationship between pathogenic CAG repeat length, 
known to be inversely correlated with age at clinical onset, and the presenting 
phenotype. Interestingly, there was no significant relationship between CAG 
length (36-59 inclusive) and the relative proportions of motor, cognitive and 
psychiatric onset cases (figure 1B and table e-2B, 
https://doi.org/10.5061/dryad.pk0p2ngkz). For the few cases with data and 
repeat lengths of more than 59 CAG we observed a more balanced 
distribution of motor, cognitive and psychiatric presentations, mirroring the 
trends seen for the juvenile HD cases. 
 
Psychiatric and cognitive symptoms captured by the Clinical 
Characteristics Questionnaire correlate with scores from validated 
clinical tools 
The HD Clinical Characteristics Questionnaire (HD-CCQ) was introduced to 
later versions of REGISTRY as the best retrospective way of capturing 
symptom data in existing HD populations. It is completed by a healthcare 
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professional using information from individuals with HD and their care 
partners, present in clinic for over 93%, about lifetime history and age at onset 
of eight symptoms typical of HD. These symptoms are motor (compatible with 
HD), depression, irritability, violent or aggressive behavior, apathy, 
perseverative/obsessive behavior, psychosis and cognitive impairment 
sufficient to impact on work or daily living. In REGISTRY, this information was 
updated at each annual clinic visit. In HD-CCQ, motor symptoms are not 
specified beyond being compatible with HD, limiting the utility of motor data, 
but psychiatric and behavioral symptoms are clearly defined. 
 
Since prevalence data from HD-CCQ have not been used in large analyses 
before we first tested how well they correlated with validated clinical scores of 
depression (HADS), irritability (SIS) and cognition (SDMT and Stroop). To 
mitigate against potential effects of medication at certain times, we used the 
lifetime highest total depression and total irritability scores for each individual. 
For cognitive tests we used scores at the last recorded clinic visit as these 
would be expected to worsen progressively and be little affected by 
medication. Total depression score from HADS was significantly increased in 
individuals with depression recorded in HD-CCQ (table 1; increase of 1.49 
units, 95% CI 1.09-1.89; P = 5.7 x 10-13). An increase in HADS score was also 
observed in individuals with HD-CCQ apathy, probably because apathy, 
common in HD, may be mistaken for depression by individuals and their care 
partners when completing the HD-CCQ. Total irritability score from SIS was 
significantly increased in individuals with HD-CCQ irritability (increase of 1.82 
units, 95% CI 1.37-2.27; P = 2.0 x 10-15), and also with violent/aggressive 
behaviour (increase of 1.57 units, 95% CI 1.08-2.06; P = 3.3 x 10-10), as 
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expected. Both SDMT and Stroop scores of cognitive ability were significantly 
decreased in individuals with cognitive impairment as recorded in HD-CCQ 
(reductions of 3.52 units, 95% CI 2.71-4.33; P = 2.3 x 10-17 and 3.41 units, 
95% CI 2-65-4.17; P = 1.4 x 10-22, respectively). Significant associations 
between cognitive scores and motor and apathy symptoms were also 
observed. In addition, we found robust and specific associations between 
neuropsychiatric symptoms recorded in HD-CCQ and their related symptoms 
scored using the validated short-form Problem Behaviors Assessment (PBA-
s; supplemental table e-4, https://doi.org/10.5061/dryad.pk0p2ngkz). The 
specificity of the associations between HD-CCQ data and recognised clinical 
scales validated the use of HD-CCQ data in subsequent analyses. 
 
Psychiatric symptoms are common in HD gene carriers and are 
associated with CAG repeat length 
We next analysed the lifetime prevalence of the eight symptoms recorded in 
HD-CCQ in 5609 individuals with HD at their most recent clinic visit (table 2). 
The mean age at last recorded clinic visit was 53.3 years; 53.5 years for 
males with data (range 10.4 – 92.6 years; N = 2569) and 53.2 years for 
females (range 7.9 – 90.2 years; N = 2698). Almost all (>99%) had 
experienced motor symptoms compatible with HD, indicating why motor 
abnormalities remain the diagnostic standard for clinical onset of HD. 
Although motor symptoms are not defined explicitly in HD-CCQ, 
contemporaneous data from UHDRS showed that 96.8% of our study 
population had chorea, alongside variable amounts of incoordination, dystonia 
and rigidity. In HD gene carriers these motor symptoms are likely to be 
specific manifestations of HD. The next most prevalent symptom was 
 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.  
 
 
depression, occurring in 64.5% of HD individuals with significantly more 
females affected than males (70.4% vs 58.2%; OR 1.70, 95% CI 1.52-1.90; P 
= 2.6 x 10-21). Cognitive impairment sufficient to impact upon work or activities 
of daily living, apathy and irritability were also each observed in over half of 
our HD population. Cognitive impairment and apathy were equally likely in 
males and females, but there was significantly more irritability observed in 
males (62.9% vs 56.9%; OR 0.78, 95% CI 0.70-0.87; P = 4.0 x 10-6). An 
excess of violent or aggressive behaviour was also observed in the male 
group (34.9% vs 27.0%; OR 0.69, 95% CI 0.62-0.77; P = 2.0 x 10-10). 
Psychosis was the least prevalent of the eight recorded symptoms, although 
this was still observed in over 11% of individuals with HD with no significant 
difference in prevalence between males and females. 
There was a strong inverse correlation between pathogenic CAG repeat 
length (40-55 CAG inclusive) and mean age at symptom onset for all 
symptoms analysed (figure 2). We found no effect of wild-type CAG allele 
length on any symptom onset, nor any significant statistical interaction 
between expanded and wild-type repeat lengths (table e-3, 
https://doi.org/10.5061/dryad.pk0p2ngkz). Pathogenic CAG length explained 
66.3% of the variance in age at onset of motor symptoms, in line with previous 
estimates2,3,17–23, but also between 37.5% and 61.9% of the variance in onset 
of each of the psychiatric symptoms analysed (table 2). Depression had the 
weakest association with CAG repeat length (R2 = 37.5%). CAG length 
accounted for significantly more of the variance in age at onset of 
perseverative/obsessive behaviour in males (table 2; P = 3.7 x 10-3) and 
irritability in females (P = 1.3 x 10-3). 
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The timing of motor and psychiatric symptoms in HD gene carriers 
varies with symptom type and CAG length 
Given that motor onset is often used as a specific milestone in the natural 
history of HD, we investigated the timing of each of the seven 
psychiatric/cognitive symptoms relative to the age at first motor symptoms 
recorded in HD-CCQ (figure 2). The differences in ages between first motor 
symptoms and each of the psychiatric symptoms were approximately normally 
distributed, with a wide range of at least +/- 20 years in each case (figures 2 
and e-2, https://doi.org/10.5061/dryad.pk0p2ngkz). In those patients reporting 
depression, onset occurred before motor symptoms in 39.2% (N= 1369/3495). 
For patients with irritability, onset occurred before motor symptoms in 30.8% 
(N= 996/3235). Perseverative/obsessive behaviour tended to occur later in 
the disease course, after motor symptoms, as did psychosis although 
numbers were smaller. Cognitive impairment and apathy had the most 
positively skewed distributions with onset occurring after motor onset in 
2179/3225 (67.6%) and 1981/2852 (69.5%) of individuals, respectively. 
Overall, 42.4% of HD patients (N= 2140/5042) reported at least one 
psychiatric or cognitive symptom in advance of motor symptoms, with a 
further 22.3% (N= 1126/5042) reporting at least one of these symptoms at the 
same time as motor abnormalities. 
 
We next assessed whether there were any patterns in the mean ages of onset 
of the different symptoms when plotted by CAG repeat length (figure 3). Some 
consistent relationships between symptoms were observed. Depression 
usually had the youngest mean age at onset, followed by motor impairment 
and then apathy and cognitive impairment as the latest symptoms. Mean age 
at onset of irritability preceded that of motor onset at shorter repeat lengths 
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(40-43 CAGs, inclusive) but tended to follow it at longer repeat lengths (44-53 
CAGs, inclusive). The mean difference in years from onset of first symptom to 
last decreased with CAG repeat length from approximately 8 years for 40 
repeats to 4 years for 55 repeats (figure 3). 
 
Cognitive and psychiatric symptoms are significantly associated with 
reduced functional capacity 
To assess whether psychiatric, cognitive or motor symptoms were associated 
with altered functional abilities we used multiple logistic regression (table 4). 
This analysis incorporated sex, pathogenic CAG length, duration of disease 
from clinical onset to last clinic visit, alcohol consumption, tobacco use, 
educational attainment, total functional capacity score and total motor score 
as predictors of the presence/absence of each HD-CCQ symptom. The 
presence of any of the psychiatric or cognitive symptoms was significantly 
associated with lower total functional capacity (TFC), an indication of impaired 
ability to work, manage personal finances and function independently. 
Cognitive impairment was most significantly associated with reduced TFC 
(OR per unit decrease in TFC = 1.28, 95% CI 1.23-1.35; P = 1.6 x 10-25). 
Depression was significantly associated with lower total motor scores 
(indicating fewer motor symptoms or signs), fitting with its prevalence early in 
the disease course. Finally, significant associations were observed between 
depression and female sex (OR = 1.77, 95% CI 1.44-2.17; P = 7.0 x 10-8) and 
tobacco use and irritability (OR per extra cigarette per day = 1.02, 95% CI 
1.01-1.03; P = 1.0 x 10-4). Although not reaching strict criteria for significance 
after correcting for multiple tests, associations were also found between male 
sex and irritability (OR = 0.75, 95% CI 0.61-0.92; P = 5.4 x 10-3) and lower 
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educational attainment and psychosis (OR per extra year of education = 0.92, 
95% CI 0.88-0.97; P = 2.2 x 10-3). 
 




In this large study of over 6000 patients we have shown that the initial 
manifestation of HD, as determined retrospectively by an expert rater, varies 
significantly with age. Late presentations (>60 years) are usually associated 
with motor abnormalities, whereas early presentations (<20 years; juvenile 
HD) are associated with a wider range of motor, cognitive and psychiatric 
abnormalities (figure 1A). These results extend prior studies which have 
shown that motor presentation of HD is common in late-onset disease (65.5% 
of an earlier REGISTRY cohort24), with more variable presentations in juvenile 
HD25,26. Approximately 20% of HD patients present with rater-determined 
psychiatric features, in line with previous findings (table e-1, 
https://doi.org/10.5061/dryad.pk0p2ngkz)9. Cognitive onset of HD might be 
under-reported in older age-groups due to it being regarded as coincident 
‘age-related’ change. Importantly, our results show there is little relationship 
between pathogenic CAG repeat length and onset type in adult-onset HD 
(figure 1B), despite both being associated with age at clinical onset. These 
data fit a model in which age at clinical onset is driven primarily by CAG 
repeat length, but modified by environmental factors and variants at other 
genomic loci14,23,27,28. The age and physiology of the brain at clinical onset 
subsequently determines the types of symptoms that become manifest. 
The HD-CCQ captures quantitative information not available elsewhere on 
symptom prevalence and timing in the HD population. Prior to its introduction 
in REGISTRY, age at first motor symptoms was not routinely recorded for all 
HD patients. HD-CCQ provides particular insight into neuropsychiatric 
symptoms but is not designed to capture the subtle early motor or cognitive 
signs found in prospective studies7,8. As it relies on retrospective reporting by 
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patients and care partners the HD-CCQ is necessarily coarse, although the 
data it generates correlate well with more precise measures of depression, 
irritability and cognition (table 1). Cognitive impairment measured by SDMT or 
Stroop correlated most strongly with lifetime history of cognitive impairment in 
HD-CCQ, as expected, but also showed significant correlations with motor 
symptoms and apathy. These results fit with other studies showing that these 
symptoms track together in the disease trajectory29,30. There was also a 
significant association between cognitive impairment and psychosis, which fits 
the cognitive deficits observed in schizophrenia31. Conversely, validated 
depression and irritability scores correlated well with their respective 
prevalence data from HD-CCQ but were not associated with motor or 
cognitive impairment (table 1). 
Almost all HD patients have specific motor abnormalities consistent with HD 
during their disease course (table 2). Psychiatric and cognitive symptoms are 
also very common (table 2), much more prevalent than in non-HD 
populations5,10,32,33, and likely underestimated due to pathological 
unawareness of these traits by HD patients34. However, clinically it is currently 
impossible to distinguish between symptoms arising as a result of the HD 
mutation and those from primary psychiatric disorders, particularly in younger 
pre-manifest patients in whom diseases such as depression are common35. 
Furthermore, environmental effects on mental health, such as living in a family 
with HD, should not be overlooked. As such, non-motor symptoms should not 
be used to make a clinical diagnosis of HD and this could even cause harm in 
vulnerable individuals with psychiatric symptoms. Future studies of psychiatric 
and cognitive symptoms and signs in HD gene carriers against gene-negative 
community controls might help define a HD-specific neuropsychiatric 
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phenotype that would enable more confident attribution of early abnormalities 
to HD. 
The age at onset of each symptom recorded by HD-CCQ was inversely 
correlated with CAG length (figure 3), with motor symptoms best correlated 
(table 3). Depression was least correlated (R2 = 37.5%), likely reflecting the 
high prevalence of the symptom in the general population independent of HD 
and the lack of use of universal diagnostic criteria. These data are consistent 
with previous reports showing that CAG length accounts for 47-72% of the 
variance in age at motor onset of HD36, but contradict previous studies that 
reported no correlation between CAG repeat length and psychiatric 
symptoms37–40. However, these studies were small and often examined 
incident psychiatric symptoms, which can fluctuate over time, rather than 
lifetime history as here. Increasingly accurate CAG tract sizing will improve 
the accuracy of correlations between repeat length and symptoms14,41,42. 
Despite considerable variation in the timing of psychiatric and motor 
symptoms, there are some conserved patterns (figures 2 & 3). Depression, 
and less often irritability, can precede motor symptoms by many years. 
Conversely, apathy and cognitive impairment tend to occur after motor 
symptoms, although patients do recognise and report these symptoms less 
readily than depression or irritability. Overall, the HD-CCQ data show that 
64.8% of our HD population (N = 3266/5042) reported at least one psychiatric 
or cognitive symptom by the time of first motor symptoms. This is a much 
higher figure than previously reported based on clinician estimates of first HD 
manifestation (figure 1)9, most likely because it is difficult to confidently 
attribute early psychiatric symptoms to HD. The overlap between HD and 
psychiatric disorders has been demonstrated by the recent finding that 
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polygenic risk scores for psychiatric diseases, particularly depression and 
schizophrenia, are associated with increased risk of corresponding psychiatric 
symptoms in HD29.  This suggests that the expanded HTT CAG repeat might 
lower the genetic threshold for manifestation of typical psychiatric 
symptoms29. In agreement, we found the expected relationships between 
female sex and depression and male sex and irritability in our cohort (table 4). 
The nominally significant negative association of psychosis in HD with 
educational level (table 4) also corroborates work showing that higher levels 
of education are associated with decreased schizophrenia risk43. 
We acknowledge several potential limitations of these data: they are 
retrospective, subject to recall bias, and cross-sectional. Furthermore, HD-
CCQ data depend on the interpretation of questions: for example, ‘motor 
symptoms’ are not explicitly defined and so although 96.8% of our population 
had chorea this was not documented in HD-CCQ. Future iterations might 
usefully subdivide ‘motor symptoms’ into (1) fidgety or jerky involuntary 
movements (chorea)’ and (2) other HD-related movement problems such as 
unsteadiness, stiffness or trouble with fine movements. Our analyses are 
based on data from the most recent clinic visit which is at different points of 
the disease course in different individuals. We controlled for this by using 
disease duration, the time between first onset and last clinic visit, as a 
covariate in analyses. The use of psychoactive medications is found in up to 
60% of HD patients and might confound motor and neuropsychiatric 
phenotypes9,44.  Of drugs prescribed for chorea, tetrabenazine can induce 
depression and antipsychotics can reduce irritability. They also suppress 
motor manifestations which might affect the total motor scores used here as a 
co-variate (table 4). It is hard to control for these effects. Drugs prescribed to 
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treat symptoms once they are present will not influence symptom onset data. 
We used worst-ever depression and irritability scores when validating the use 
of HD-CCQ to mitigate against the effects of medication prescribed at certain 
times. 
Previous prospective studies of phenotype in HD such as PREDICT-HD and 
TRACK-HD have shown subtle early reductions in psychiatric and cognitive 
function years in advance of clinical onset7,8. The HD-CCQ accesses 
retrospective data from large existing populations of manifest HD patients and 
shows similar trends. Since the HD-CCQ is part of ongoing longitudinal 
observational studies such as ENROLL-HD, future analyses of larger 
populations will be possible and of benefit. The presence of psychiatric and 
cognitive symptoms in HD gene carriers is associated with significantly 
reduced functional capacity, emphasizing the importance of early recognition 
and management of these symptoms45,46. Although recent models of HD 
staging and progression do not directly include psychiatric and cognitive 
symptoms47–49, work is underway to include them in ongoing observational 
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Table 1.  Association of validated clinical scores with the HD Clinical Characteristics 3 
Questionnaire symptoms (shown in italics), and other covariates. For binary 4 
covariates (CCQ symptoms and sex) “effect” is the increase/decrease in the clinical 5 
score associated with presence of that covariate. For quantitative covariates (age, 6 
CAG, duration), “effect” is the change in clinical score associated with an increase of 7 
one unit in the covariate. In addition to having a confirmed onset and pathogenic 8 
CAG length (36-93), individuals must have no co-morbid diagnosis of schizophrenia, 9 
schizotypy or schizoaffective disorder. Significant associations after Bonferroni 10 
correction for 4 phenotypes and 12 covariates are shown in bold (P < 1.04 x 10-3) 11 
and nominally significant P values are italicised (P < 0.05). CI: confidence interval; 12 
TDS: Total depression score from the Hospital Anxiety and Depression Scale; TIS: 13 
Total irritability score from Snaith’s irritability scale; SDMT: Symbol digits modalities 14 
test; POB: perseverative/obsessive behaviour; VAB: violent or aggressive behaviour; 15 
Sex (F): female.16 
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    Males   Females       
    Yes No Frequency   Yes No Frequency   OR 
(95% CI) 
P value (c2) 
Motor 
 
2691 28 98.97% 
 
2859 25 99.13% 
 
1.19 (0.69 - 2.05) 5.29 x 10-1 
Cognitive 
 
1584 1132 58.32% 
 
1688 1187 58.71% 
 
1.02 (0.91 - 1.13) 7.66 x 10-1 
Apathy 
 
1456 1259 53.63% 
 
1495 1374 52.11% 
 
0.94 (0.85 - 1.05) 2.56 x 10-1 
Depression  1582 1135 58.23%  2025 853 70.36%  1.70 (1.52 - 1.90) 2.57 x 10
-21 
POB  1005 1711 37.00%  1038 1834 36.14%  0.96 (0.86 - 1.07) 5.04 x 10
-1 




947 1769 34.87% 
 
777 2100 27.01% 
 
0.69 (0.62 - 0.77) 1.99 x 10-10 
Psychosis   319 2396 11.75%   325 2549 11.31%   0.96 (0.81 - 1.13) 6.06 x 10-1 
 1 
Table 2.  Lifetime prevalence of motor and psychiatric symptoms in males and 2 
females with HD. Data from HD Clinical Characteristics Questionnaire at last 3 
recorded clinic visit in Registry. Chi-square (c2) tests the difference between 4 
prevalence in males and females. Odds ratios (OR) >1 indicates the symptom is 5 
more common in females; odds ratios <1 indicates the symptom is more common in 6 
males. To be included, individuals must have a pathogenic CAG length (36-93) and 7 
confirmed clinical HD onset. Significant P values in bold (P < 6.25 x 10-3, multiple 8 
testing correction). CI: confidence interval; POB: perseverative/obsessive behaviour; 9 
VAB: violent or aggressive behaviour.10 
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    Male   Female   P   Both   
    R2 (95% CI) N   R2 (95% CI) N      R
2 (95% CI) N   
Motor 0.678 (0.657 - 0.697) 2684  
0.649 
(0.628 - 0.670) 2844  5.42 x 10
-2  
0.663 
(0.648 - 0.677) 5528 
Cognitive 0.610 (0.579 - 0.639) 1570  
0.629 
(0.600 - 0.656) 1681  3.80 x 10
-1  
0.619 
(0.598 - 0.639) 3251 
Apathy 
0.595 
(0.562 - 0.627) 1423  
0.562 
(0.528 - 0.595) 1462  1.83 x 10
-1  
0.578 
(0.554 - 0.601) 2885 
Depression 0.412 (0.374 - 0.449) 1551  
0.351 
(0.318 - 0.385) 1994  3.50 x 10
-2  
0.375 
(0.350 - 0.400) 3545 
POB 
0.539 
(0.496 - 0.581) 973  
0.440 
(0.394 - 0.485) 1016  
3.67 x 10-3  
0.489 
(0.457 - 0.52) 1989 
Irritability 0.463 (0.428 - 0.498) 1670  
0.547 
(0.513 - 0.579) 1601  1.25 x 10
-3  
0.503 
(0.478 - 0.527) 3271 
VAB 0.479 (0.431 - 0.524) 927  
0.478 
(0.426 - 0.528) 761  9.79 x 10
-1  
0.477 
(0.442 - 0.511) 1688 
  Psychosis 
0.401 
(0.316 - 0.484) 312   
0.424 
(0.340 - 0.504) 318   7.29 x 10
-1   
0.411 
(0.351 - 0.469) 630   
 1 
Table 3.  Variance in age at onset (R2) explained by pathogenic CAG repeat length 2 
for eight symptoms in males and females with HD. Ages at onset were 3 
logarithmically transformed and plotted against CAG length. P values test difference 4 
between male and female R2. Significant P values (P < 6.25 x 10-3; multiple testing 5 
correction) are in bold and nominally significant P values (P < 0.05) italicised. 6 
Individuals had to have a clinical onset of HD, a known sex and a pathogenic CAG 7 
length (36-93) to be included. CI: confidence interval; POB: perseverative/obsessive 8 
behaviour; VAB: violent or aggressive behaviour. 9 
 10 
 











OR (95% CI) P 
 
OR (95% CI) P 
 
OR (95% CI) P 
 
Sex (F) 0.49 (0.14 - 1.66) 2.51 x 10-1  1.20 (0.97 - 1.49) 9.75 x 10
-2  1.07 (0.87 - 1.31) 5.13 x 10
-1  
CAG 0.95 (0.83 - 1.10) 5.10 x 10-1  1.01 (0.98 - 1.03) 6.64 x 10
-1  0.99 (0.96 - 1.01) 2.32 x 10
-1  
Duration 0.91 (0.82 - 1.01) 8.32 x 10-2  1.00 (0.98 - 1.03) 6.99 x 10
-1  1.00 (0.98 - 1.02) 8.96 x 10
-1  
Alcohol 1.00 (0.93 - 1.08) 9.61 x 10-1  1.02 (1.01 - 1.04) 8.78 x 10
-3 
 
1.00 (0.99 - 1.02) 5.56 x 10-1  
Tobacco 1.10 (0.96 - 1.26) 1.54 x 10-1  1.01 (0.99 - 1.02) 3.00 x 10
-1  1.02 (1.00 - 1.03) 4.94 x 10
-3  
Education 0.89 (0.75 - 1.06) 1.97 x 10-1  1.01 (0.98 - 1.05) 4.03 x 10
-1  0.98 (0.95 - 1.01) 2.02 x 10
-1  
TFC 1.05 (0.75 - 1.46) 7.85 x 10-1  0.78 (0.74 - 0.81) 1.58 x 10
-25  0.87 (0.84 - 0.91) 1.14 x 10
-9  










OR (95% CI) P 
 
OR (95% CI) P 
 
OR (95% CI) P 
 
Sex (F) 1.77 (1.44 - 2.17) 6.98 x 10-8  1.07 (0.86 - 1.32) 5.68 x 10
-1  0.75 (0.61 - 0.92) 5.36 x 10
-3  
CAG 0.96 (0.93 - 0.98) 1.32 x 10-4 
 
1.00 (0.97 - 1.02) 6.93 x 10-1 
 
0.99 (0.97 - 1.01) 4.74 x 10-1 
 
Duration 1.03 (1.01 - 1.05) 1.10 x 10-2  
1.03 (1.00 - 1.05) 1.68 x 10-2  
1.03 (1.01 - 1.05) 6.84 x 10-3  
Alcohol 0.99 (0.98 - 1.01) 2.66 x 10-1 
 
1.00 (0.99 - 1.02) 5.14 x 10-1 
 
1.01 (0.99 - 1.02) 4.79 x 10-1 
 
Tobacco 1.02 (1.01 - 1.03) 8.14 x 10-4  
1.01 (1.00 - 1.02) 2.04 x 10-1 
 
1.02 (1.01 - 1.03) 1.02 x 10-4 
 
Education 0.99 (0.96 - 1.02) 5.83 x 10-1  1.00 (0.97 - 1.03) 8.21 x 10
-1  1.00 (0.97 - 1.03) 8.44 x 10
-1  
TFC 0.90 (0.86 - 0.94) 7.30 x 10-6 
 
0.89 (0.85 - 0.93) 1.10 x 10-6  0.93 (0.89 - 0.97) 8.83 x 10
-4  








OR (95% CI) P 
 
OR (95% CI) P 
 
Sex (F) 0.75 (0.60 - 0.94) 1.27 x 10-2  0.81 (0.57 - 1.14) 2.23 x 10
-1  
CAG 1.00 (0.98 - 1.02) 9.42 x 10-1 
 
0.99 (0.95 - 1.02) 4.84 x 10-1 
 
Duration 1.04 (1.02 - 1.06) 9.10 x 10-4  
1.02 (0.98 - 1.05) 3.47 x 10-1 
 
Alcohol 1.00 (0.99 - 1.01) 9.29 x 10-1 
 
1.02 (1.00 - 1.04) 3.35 x 10-2 
 
Tobacco 1.02 (1.01 - 1.03) 2.08 x 10-3  1.00 (0.98 - 1.02) 8.38 x 10
-1  
Education 0.99 (0.95 - 1.02) 3.69 x 10-1  0.92 (0.88 - 0.97) 2.24 x 10
-3  
TFC 0.88 (0.84 - 0.93) 2.07 x 10-7 
 
0.83 (0.77 - 0.89) 3.33 x 10-7  
TMS 0.99 (0.99 - 1.00) 7.49 x 10-2   0.99 (0.98 - 1.00) 1.47 x 10-1   
 3 
Table 4.  Psychiatric and cognitive symptoms are associated with reduced functional 4 
capacity. Multiple logistic regression using binary HD-CCQ data for 8 symptoms (0 = 5 
no symptom; 1 = reported symptom) and clinical covariates. Significant associations 6 
after Bonferroni correction for 8 symptoms and 8 covariates are shown in bold (P < 7 
7.81 x 10-4) and nominally significant associations in italics (P < 0.05). With the 8 
exception of sex, the odds ratio (OR) indicates the effect on the outcome probability 9 
associated with an increase of one unit in the covariate. In addition to having a 10 
confirmed onset and pathogenic CAG length (36-93), individuals must have no co-11 
morbid diagnosis of schizophrenia, schizotypy or schizoaffective disorder. CI: 12 
confidence interval; Sex (F): female; POB: perseverative/obsessive behaviour; TFC: 13 
total functional capacity; TMS: total motor score; VAB: violent or aggressive 14 
behaviour. 15 
 





Figure 1. The initial manifestation of HD varies with age and CAG length.  
All included individuals had a pathogenic CAG length (36-93) and confirmed HD 
onset age determined by a rating clinician. (A) Frequency of different onset types in 
four age groups, chosen to show juvenile HD and then 20 year bins for clarity. Total 
N=6289; <20 years, N=188; 20-40 years, N=2216; 40-60 years, N=3276; >60 years, 
N=609. (B) Frequency of different onset types in six CAG length groups, chosen for 
clarity across the pathogenic range. Total N=6289; 36-39 CAG, N=156; 40-44 CAG, 








Figure 2. The onsets of cognitive and psychiatric symptoms relative to motor 
onset in HD.  
The age at onset of motor symptoms was subtracted from the age at onset of each 
cognitive/psychiatric symptom when present. Timings of up to +/- 40 years relative to 
motor onset shown. Only individuals with a rater-confirmed age at onset and CAG 
length (36-93) were included. Data from HD-CCQ. (A) Cognitive impairment 
N=3225; (B) Apathy N=2852; (C) Depression N=3495; (D) Irritability N=3235.  
 
 







Figure 3. Mean ages at onset for motor and psychiatric symptoms at different 
CAG repeat lengths.   
Shown are the mean ages at symptom onset as recorded by the HD Clinical 
Characteristics Questionnaire for apathy (N = 2739), cognitive impairment (N = 
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